Neuroendocrine Responses to Physostigmine in Alzheimer's Disease

Murray A. Raskind, Elaine R. Peskind, Richard C. Veith, Steven C. Risse, Thomas H. Lampe, Soo Borson, Gail Gumbrecht, Daniel M. Dorsa

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


To assess central nervous system cholinergic neuroendocrine regulation in Alzheimer's disease (AD), we measured plasma arginine vasopressin, β-endorphin, and epinephrine responses to a cholinergic challenge elicited by intravenous administration of the acetylcholinesterase inhibitor physostigmine (0.0125 mg/kg) in male patients with AD (n =12) and compared their responses with those of age-matched normal control subjects (n =12). Physostigmine promptly increased plasma arginine vasopressin (tenfold), β-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. In contrast, patients with AD showed attenuated responses to physostigmine. When controls and patients with AD who experienced nausea (n = 2 and n = 6, respectively) were excluded, the arginine vasopressin, β-endorphin, and epinephrine responses of patients with AD were significantly less than those of control subjects. These data suggest that the central nervous system cholinergic deterioration of AD results in decreased responsiveness of neuroendocrine systems that are regulated by central cholinergic mechanisms.

Original languageEnglish (US)
Pages (from-to)535-540
Number of pages6
JournalArchives of General Psychiatry
Issue number6
StatePublished - Jun 1989


Dive into the research topics of 'Neuroendocrine Responses to Physostigmine in Alzheimer's Disease'. Together they form a unique fingerprint.

Cite this